EP Patent

EP3714877A1 — Method and composition for treating ocular hypertension and glaucoma

Assigned to Santen Pharmaceutical Co Ltd · Expires 2020-09-30 · 6y expired

What this patent protects

The present invention relates to a preservative-free ophthalmic aqueous composition containing prostaglandin (PG hereafter) F2α analogues for treating ocular hypertension and glaucoma.

USPTO Abstract

The present invention relates to a preservative-free ophthalmic aqueous composition containing prostaglandin (PG hereafter) F2α analogues for treating ocular hypertension and glaucoma.

Drugs covered by this patent

Patent Metadata

Patent number: EP3714877A1
Jurisdiction: EP
Classification: —
Expires: 2020-09-30
Drug substance claim: No
Drug product claim: No
Assignee: Santen Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.